Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

apatinib

Known as: 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1) 
An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
  • Jin Li, Shukui Qin, +31 authors Hao Yu
  • Journal of clinical oncology : official journal…
  • 2016
  • Corpus ID: 3583362
PURPOSE There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Tumor cells co-express vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) that interact each other to support… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
The Rearranged during transfection (RET) fusion gene is a newly identified oncogenic mutation in non-small cell lung cancer… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2015
Review
2015
Aberrant proangiogenic pathways have long been implicated in tumorigenesis and metastasis. Antiangiogenic therapies have shown… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Apatinib is an oral, highly potent tyrosine-kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
  • Jin Li, Shukui Qin, +15 authors Hao Yu
  • Journal of clinical oncology : official journal…
  • 2013
  • Corpus ID: 35265297
PURPOSE Patients with metastatic gastric cancer (mGC) who do not respond to or who experience progression with second-line… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BackgroundApatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). This study… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Apatinib is a new oral antiangiogenic molecule that inhibits vascular endothelial growth factor receptor-2. The present study… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
P-glycoprotein (P-gp, ABCB1) overexpression and enrichment of stem-like cells are linked to poor prognosis in tumor patients. In… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Apatinib, a small-molecule multitargeted tyrosine kinase inhibitor, is in phase III clinical trial for the treatment of patients… Expand
Is this relevant?